Moderator
Mark Sales, Oracle, Reading, United Kingdom
Speakers
Raoh-Fang Jasmine Pwu, MS, PhD, Fu Jen Catholic University, Taipei, Taiwan; Mie Azuma, Eisai Co., Ltd., Tokyo, Japan; Julie Van Bavel, Merck Sharp & Dohme Australia (MSD Australia) Pty Ltd, New South Wales, Australia
The Issue:
The societal burden of disease extends significantly beyond direct medical costs and clinical outcomes, encompassing substantial impacts on patients, families, and the wider community. While Health Technology Assessment (HTA) bodies globally, and particularly in the Asia-Pacific region, have historically adopted a narrower perspective in cost-effectiveness analyses, leading think-tanks such as ISPOR and the Office of Health Economics (OHE) advocate for the systematic inclusion of broader value elements. These include caregiver burden, productivity losses, and indirect non-medical costs, which are critical for a comprehensive societal perspective.
Description of symposium:
This symposium will address the methodological imperative of thoughtfully integrating patient and caregiver-generated data into real-world evidence (RWE) frameworks. We will explore robust approaches to quantify the holistic impact of disease and the value of interventions, moving beyond traditional endpoints. The session will critically examine challenges in the APAC context, including developing consensus, refining methodologies, standardizing instrument selection for patient-reported outcomes (PROs) and caregiver-reported outcomes (CaROs), and augmenting the capacity of HTA bodies. Discussion will focus on innovative strategies to leverage these rich data sources to inform more inclusive Cost of Illness (COI) studies and enhance the demonstration of therapeutic value from a societal standpoint.
Sponsored by Oracle Life Sciences
Code
19
Topic Subcategory
Distributed Data & Research Networks